Ondansetron Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron Kabi is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways associated with several clinical settings.

• Chemotherapy‑induced nausea and vomiting: Reduces the frequency and severity of acute and delayed episodes.
• Radiotherapy‑induced nausea and vomiting: Helps control nausea during and after radiation treatment.
• Post‑operative nausea and vomiting: Decreases incidence of nausea and vomiting after surgical procedures.
• Pregnancy‑related hyperemesis gravidarum: Provides symptomatic relief when other measures are insufficient.
• Anticipatory nausea: Lessens nausea that occurs before chemotherapy in patients with prior experience.

• Ondansetron blocks the action of serotonin at the 5‑HT3 receptors located on vagal nerve terminals in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By preventing receptor activation, it interrupts the signaling cascade that initiates the vomiting reflex, thereby reducing nausea and vomiting associated with chemotherapeutic agents, radiation, and surgical stress.

Side effects reported with ondansetron are generally mild to moderate and vary with the route of administration and patient population.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: occasional bowel habit changes.
• Diarrhoea: transient loose stools.
• Fatigue: feeling of tiredness or reduced energy.
• Dizziness: light‑headed sensation.
• Injection site reactions: erythema or mild pain at the IV site.

Serious or Rare Side Effects

• Cardiac arrhythmia: QT‑interval prolongation, especially with rapid IV administration.
• Severe allergic reaction: anaphylaxis, urticaria, or angio‑edema.
• Serotonin syndrome: rare when combined with other serotonergic agents.
• Hepatic enzyme elevation: abnormal liver function tests.
• Severe hypotension: abrupt drop in blood pressure following rapid infusion.

When using Ondansetron Kabi, clinicians should consider several safety aspects to optimise patient outcomes.

• Cardiac monitoring: assess baseline ECG in patients with known cardiac disease or electrolyte disturbances.
• Electrolyte balance: correct hypokalaemia, hypomagnesemia, or hypocalcaemia before administration.
• Concomitant serotonergic drugs: evaluate risk of serotonin syndrome.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Pediatric dosing: ensure weight‑based calculations are performed by the prescriber.
• Store at below 25°C: keep in the original packaging, protect from light and moisture.

Ondansetron may interact with several medicines that influence cardiac conduction or serotonergic pathways.

Major Interactions (Avoid)

• Amiodarone: may increase risk of QT prolongation.
• Certain anti‑malarial    ---

Moderate  ---